Neurosarcoidosis
ICD-10 G53.2 · ICD-11 4B20.3

Treatment of Neurosarcoidosis in Acutely and Severely Ill Patients with Severe Disabling Neurologic Disease

Clinical Scenario

This protocol addresses patients with neurosarcoidosis who are acutely and severely ill, presenting with severe disabling neurologic disease — a presentation that warrants prompt, intensive management.

Treatment Approach

In this acute, severe setting, the approach centres on anti-TNF biologic therapy. The complete regimen, clinical criteria for each option, and the full decision framework are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. For patients who are acutely and severely ill, intravenous methylprednisolone for three days or anti-TNF therapy is recommended.
  2. Infliximab can also be used for chronic treatment or to “bridge” a patient until an immunosuppressive drug’s benefit becomes evident, typically in 2–3 months.
  3. Infusions of infliximab can be administered every 2–8 weeks, or at longer intervals, as clinically indicated.
View source ↗